Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system leading to inflammation and destruction of myelin and axons [1]. A worldwide average incidence of 2.5 per 100,000 people with a variance of 1.1–4.0 and a prevalence of 30.0 per 100,000 people with a variance of 5.0–80.0 is estimated (Word Health Organization, 2008). The relapsing-remitting (RRMS) course of the disease is typically characterized by recurrent acute episodes with neurologic symptoms, followed by complete or partial recovery.

Fingolimod (FTY720, brand name Gilenya^® Novartis Pharma AG, Basel, Switzerland) has been approved for the treatment of RRMS. The safety profile of fingolimod has been proven by treatment of over 30,000 MS patients in clinical studies. Altogether, worldwide, more than 148,000 patients were treated with the substance, according to an experience of 316,000 patient years (data obtained from Q1 Novartis Pharmaceuticals Interim Financial Report, April 2016).

Due to the expression of sphingosine 1-phosphate receptors on cardiomyocytes, it was known that the first dose of fingolimod may lead to a transient, usually asymptomatic bradycardia and may possibly trigger rare and self-limited atrioventricular-blocks (AV blocks) [2‐4]. Therefore, the European Medicines Agency recommended a 6 h continuous cardiac monitoring after the first administration of fingolimod.

Therefore, the aims of this non-interventional study (NIS) were the following: (1) to assess the cardiac risk profile in RRMS patients who intended to be treated with fingolimod, (2) to assess the cardiac safety profile in RRMS patients during at least 6 h after the initial treatment or restart after interruption, and (3) to assess the adherence of treating physicians regarding the new cardiovascular monitoring.

From February 2012 to April 2015, 217 patients were enrolled at 42 study centers (5.2 ± 5.5 patients/center). The mean age of the 58 males (26.7%) and 159 females (73.3%) included was 39.8 ± 9.8 years (see Table 1). Data on MS history are also summarized in Table 1. For the evaluation of the cardiac risk profile, the history of cardiovascular risk factors in patients and their families was assessed. A family history of cardiovascular risk factors was reported in 43.8% of the patients, mostly hypertension (66 patients, 30.4%) and diabetes mellitus (35 patients, 16.1%). A cardiovascular risk factor was directly observed in 78 patients (35.9%), mostly tobacco use (40 patients, 18.4%), overweight (27 patients, 12.4%), and hypertension (24 patients, 11.1%). Ten patients (4.6%) had a history of cardiac arrhythmias. Twenty nine (13.4%) of the 217 patients enrolled took concomitantly cardiovascular medication, mainly antihypertensive (25 patients, 11.5%), beta blockers (two patients, 0.9%), calcium-channel blockers (one patient, 0.5%), or lipid-lowering drugs (eight patients, 3.7%).

ECG examinations were mainly performed by cardiologists (61.7% and 62.7%), followed by neurologists (16.2% and 16.6%), general practitioners (13.1% and 10.6%), and specialists in internal medicine (8.1% and 8.3%). Overall, more than 95% of physicians adhered to the cardiac monitoring recommendations.

Course of blood pressure and HR course at baseline and during the 6 h observation period are summarized in Fig. 1a and b. The detailed HR course is also represented in Table 2. During the observation period, blood pressure remained relatively stable; only a slight decrease in the mean blood pressure (systolic and diastolic) was observed (Fig. 1a). The lowest mean systolic blood pressure (120.4 ± 13.9 mmHg) was observed, 2 h after treatment start and 5 h after treatment start, the lowest mean diastolic blood pressure (76.7 ± 10.0 mmHg). Patients receiving the first dose of fingolimod experienced, on average, a slight and transient decline in HR (Table 2; Fig. 1b). These patients had a maximum mean decline in HR of 9.2 beats per minute (BPM) from 74.9 ± 11.5 to 65.8 ± 9.9 BPM with the lowest values measured at 5 h after application.

Overall, 33 patients (15.2%) were documented with cardiac events during or at the end of the observation period, summarized in Table 3 (including asymptomatic blood pressure increase or HR increase) [data on file, (Novartis Pharma GmbH, Nürnberg, Germany)]. None of the patients displayed a new or persistent onset AV block [2nd degree (Mobitz type I) or 3rd degree] or QTc ≥500 ms. Bradycardia, defined as a decrease in HR <45 BPM during or at the end of the observation period, was reported for four and three patients (1.8% and 1.4%, respectively). “Other” cardiac events were documented for nine and four patients (4.3% and 1.8%, respectively) during or at the end of the observation period. These events mostly referred to a low HR which did, however, not meet the criteria of a bradycardia (45–60 BPM) or AV block other than 2nd or 3rd degree (i.e. AV-block 1st degree). None of these patients had any cardiovascular risks/history or took HR-lowering co-medication.

Here, we analyze the cardiac side effects after the first dose of fingolimod in everyday practice and confirm the well-known favorable cardiac safety profile of this compound in a real-world setting. None of the few cardiac events in this study required medical attention. The positive cardiac safety profile also extended to blood pressure analyses with only mild changes in systolic and diastolic blood pressure and even to the 35.9% of patients in the study with any cardiac risk factor (mainly tobacco use, overweight, hypertension, or patients taking cardiovascular co-medications, see Table 1). The particular strength of this non-interventional study is that it encompasses patients with pre-existing cardiac risk factors, who are excluded from the majority of clinical studies investigating fingolimod. This cardiac safety profile, including the observed episodes of bradycardia and the few other cardiac events, is consistent with the data of the first-dose monitoring from pivotal phase III trials and from a phase IIb multi-center study as well as post-marketing experience from the ongoing START Study (ClinicalTrials.gov identifier, NCT01585298; a prospective, one-week, multi-center, open-label study enrolling up to 7000 patients with RRMS in more than 250 centers in Germany, which already analyzed data of 3.951 patients) [2, 3, 6‐10]. The absence of an increased QTc period is also consistent with the previous findings from rat models [11].

Very encouraging is also the following result: from the 35.9% of patients who shared any cardiac risk profile (especially those having a history of hypertension or arrhythmia), none experienced bradycardia during the 6 h post-dose observation, including those who were under HR-lowering co-medication. Overall, only 1.8% of all patients in this small cohort displayed bradycardia (HR ≤45 BPM) during the 6 h post-dose observation. Analyses from other studies in “real-life” settings provide further evidence on fingolimod treatment initiation. Data of the first study (ClinicalTrials.gov identifier, NCT01497262), which also enrolled RRMS patients taking calcium-channel blockers and beta blockers (n = 2417), showed an increased frequency of bradycardia in patients receiving these cardiovascular co-medications [4]. This observation was not seen in our study, which may be limited by its lower number of participants. However, our results are in agreement with the data of other recent observations in real-life settings. For example, data of an Italian study assessing the safety and tolerability of fingolimod after first dose (n = 906) revealed that the concomitant use of drugs which may cause bradycardia or otherwise influence cardiac conduction was not associated with cardiac events during the first-dose observation [12]. Other studies in real-life settings also demonstrate the rare occurrence of cardiac events after the first dose of fingolimod and their self-limited character [2, 3, 12‐17], thus corroborating the very favorable cardiac safety profile of fingolimod.

Another strength of this study refers to the ECG data collection obtained in real-world settings which prove that the recommended cardiovascular observation after the first administration of fingolimod in office-based settings is feasible and also adhered to.

Possible limitations of this study lie in the lower than expected number of recruited patients. It was planned to include approximately 2000 patients over a 3-year period. Only 217 patients were enrolled at 42 study centers possibly due to competing studies and the widespread use of fingolimod outside of study settings in everyday practice. This lower number of enrolled patients may affect the detection of possible rare AEs. Yet, few missing data and good compliance to the recommendations in the summary of product characteristics during this NIS indicate a good reliability of the results.

In summary, these data confirm: (1) the feasibility of ECG monitoring for the fingolimod initiation in real-life settings and (2) that the first-dose observation after the fingolimod initiation is usually uneventful (even in patients with pre-existing cardiovascular risk factors of this cohort). Rare cardiac events remained asymptomatic and self-limited.